N/A
Completed N=880
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
Source: ClinicalTrials.gov NCT01065779 ↗Enrolled (actual)
880
Serious AEs
0.0%
Results posted
Sep 2011
Primary outcomePrimary: Number of Participants With Serious Adverse Events — 0 Participants
Summary
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS D through collecting the safety information according to the Re-examination Regulation for New Drugs.
Note: FOSAMAX PLUS D is known as FOSAMAX PLUS in several markets. FOSAMAX PLUS (70 mg/2800 IU) and FOSAMAX PLUS D (70 mg/5600 IU).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Serious Adverse Events |
— | — |
| PRIMARY Number of Participants With Unexpected Adverse Events |
2 | — |
| PRIMARY Number of Participants With Non-Serious AEs |
42 | — |
| PRIMARY Number of Participants With Improved, Unchanged, or Worsened Disease |
549; 239; 1 | — |
| PRIMARY Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment |
1.73 | — |
| PRIMARY Change From Baseline in Serum Osteocalcin at End of Treatment |
0.69 | — |
| PRIMARY Change From Baseline in Urine Deoxypyridinoline at End of Treatment |
1.03 | — |
| PRIMARY Change From Baseline in Alkaline Phosphatase at End of Treatment |
-16.36 | — |
Eligibility Criteria
Inclusion Criteria
- Participants who are treated with FOSAMAX PLUS / FOSAMAX PLUS D within label for the first time
Exclusion Criteria
- Participants who have a contraindication to FOSAMAX PLUS / FOSAMAX PLUS D according to the current local label
Data sourced from ClinicalTrials.gov (NCT01065779). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.